Most Popular

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

Save

Safety comparisons of JAKi (tofacitinib) vs.

Serologically Active, Clinically Quiescent SLE

Save

Lupus management is guided by assessment of both clinical and serologic features; but what happens with the patient with systemic lupus erythematosus (SLE) serologically active, but clinically quiescent (SACQ)?  A large cohort study shows that nearly one-third of such patients may flare and may r

Management of Immune-Related Adverse Events - ASCO Guideline

Save

The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.

ACR21 Best Abstracts - Day 1

Save

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

An Old Friend – Methotrexate in Psoriatic Arthritis

Save

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as psoriatic arthritis (PsA).

RheumNow Podcast – Like Father, Like Daughter (10.29.2021)

Save

Dr. Jack Cush reviews the news and journal articles from the past week and discusses parent-child rheumatologists pairs.

Top vasculitis takeaways from ACR 2021

Save

There were several hot topics and it is difficult to give all the top abstracts, so I will concentrate on vasculitis. 

Giant cell arteritis

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Save

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Abstract Numbers below:

Psoriatic arthritis

Day 2 Report from ACR21

Save

Highlight reports from Sunday, Day 2 at ACR Convergence included:

VITAL Trial: Vitamin D and n-3 Fatty Acid Supplements Protect Against Autoimmune Disease

Day 1 Report from ACR21

Save

The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.  To hear more about the best of the best, I would encourage you to look at our

GLORIA Study - Is Prednisone Harmful in Elder RA?

Save

The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.

ACR21 Best Abstracts We Saw - Day 3 (Monday)

Save

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

ACR21 Best Abstracts - Day 4

Save

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports:

TNF inhibitors and radiographic progression in axSpA

Save

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axial spondyloarthritis (ax-Spa), whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Opening Day Report

Save

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

New Insights into Uveitis in Spondyloarthritis

Save

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

ACR21 – Day 3 Report

Save

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:

Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.

Day 4 Report from ACR21

Save

My favorite three presentations from day 4 at ACR 2021 included the following:

Breakthrough Infections in Rheumatic Disease Patients

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Save

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremilast). 

Can "Ultra-low" dose Rituximab work for RA?

Save

At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art